ArticleTrials2020
Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03778554 (Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK)
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Beta-blockers in patients without heart failure after myocardial infarction.The Cochrane database of systematic reviews · 2021Pooled it
- Contemporary Antianginal Therapy.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- [Beta-blockers following myocardial infarction without heart failure: their role in the era of coronary reperfusion].Innere Medizin (Heidelberg, Germany) · 2026Review
- Acute Myocardial Infarction: Molecular Pathogenesis, Diagnosis, and Clinical Management.MedComm · 2025Review
- Effect of metoprolol exposure following myocardial infarction on future cardiovascular events: a Mendelian randomization study.European journal of clinical pharmacology · 2025Article
- Article
- Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2024Review
- 2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes.Korean circulation journal · 2024Review
- Article
- Management of Acute Coronary Syndromes in Older People: Comprehensive Review and Multidisciplinary Practice-Based Recommendations.Journal of clinical medicine · 2024Review
- Comparative Effectiveness of Long-Term Maintenance Beta-Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention.Journal of the American Heart Association · 2023Article
- Long-Term Follow-Up After Acute Myocardial Infarction According to Beta-Blocker Dose.The American journal of medicine · 2023Article
- Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis.Cardiology and therapy · 2023Article
- Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study.European heart journal · 2023Article
- Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI).European heart journal. Cardiovascular pharmacotherapy · 2023Article
- Role of β-blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction.Current cardiology reviews · 2023Review
- Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry.European heart journal. Cardiovascular pharmacotherapy · 2022Article
- Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study.European heart journal. Cardiovascular pharmacotherapy · 2022Observational
- Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It.Reviews in cardiovascular medicine · 2022Review
- Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease-A randomized controlled trial.International Journal of Cardiology. Hypertension · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 14 institutions in 4 countries.
Funding
Abstract
backgroundTreatment with beta-blockers is currently recommended after myocardial infarction (MI). The evidence relies on trials conducted decades ago before implementation of revascularization and contemporary medical therapy or in trials enrolling patients with heart failure or reduced left ventricular ejection fraction (LVEF ≤ 40%). Accordingly, the impact of beta-blockers on mortality and morbidity following acute MI in patients without reduced LVEF or heart failure is unclear. METHODS/
designThe Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) is a prospective, randomized, controlled, open-label, non-blinded endpoint clinical trial designed to evaluate the efficacy of beta-blocker treatment in post-MI patients in the absence of reduced LVEF or heart failure. We will randomize 3570 patients will be randomized within 14 days of index MI to beta-blocker or control for a minimum of 2 years. The primary endpoint is a composite of all-cause mortality, recurrent MI, acute decompensated heart failure, unstable angina pectoris, or stroke. The primary composite endpoint will be assessed through locally reported and adjudicated endpoints supplemented by linkage to the Danish national registers. A number of secondary endpoints will be investigated including patient reported outcomes and cardiovascular mortality. Data from similar ongoing trials in Norway and Sweden will be pooled to perform an individual patient data meta-analysis. DISCUSSION: DANBLOCK is a randomized clinical trial investigating the effect of long-term beta-blocker therapy after myocardial infarction in patients without heart failure and reduced LVEF. Results from the trial will add important scientific evidence to inform future clinical guidelines.
trial registrationClinicaltrials.gov, NCT03778554. Registered on 19 December 2018. European Clinical Trials Database, 2018-002699-42, registered on 28 September 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.